AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 21.65 |
| Open | 21.60 |
| Bid | 17.15 x 4000 |
| Ask | 30.20 x 1800 |
| Day's Range | 21.60 - 22.25 |
| 52 Week Range | 11.93 - 25.63 |
| Volume | 261,908 |
| Avg. Volume | 746,926 |
| Market Cap | 756.902M |
| Beta | 0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.22 |
- Moody's•10 hours ago
GI Chill Acquisition LLC -- Moody's assigns a B3 CFR to GI Chill Acquisition LLC; stable outlook
Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton, and II-VI — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
- The Wall Street Journal•last month
[$$] GI Partners Buys Cord Blood Registry and Sperm and Egg Bank
GI Partners is buying two medical-storage companies to take advantage of the growing reproductive sciences field. GI is also buying California Cryobank, a donor sperm and egg bank, from health-care investors Longitude Capital and NovaQuest Capital, for an undisclosed amount. California Cryobank’s donor sperm and egg banks have worked with more than 75,000 families since 1977.
- PR Newswire•last month
California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
- GlobeNewswire•last month
AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. “The divestiture of CBR is an important step as we execute on AMAG's strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG.
- ACCESSWIRE•last month
Initiating Free Research Reports on ArQule and Three Other Biotech Equities
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
- GlobeNewswire•last month
AMAG Pharmaceuticals, Inc. and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies
AMAG Pharmaceuticals, Inc. (AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program. “AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies.
- GlobeNewswire•last month
AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee Act (PDUFA) date for completion of FDA review of the bremelanotide NDA is March 23, 2019.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th at 3:30 p.m. ET. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause
WALTHAM, Mass., May 09, 2018-- AMAG Pharmaceuticals, Inc. today commended the recent action taken by the Centers for Medicare and Medicaid Services to clarify statutory intent of section§ 1860 D-2 of the ...
- ACCESSWIRE•2 months ago
Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AMAG earnings conference call or presentation 3-May-18 12:00pm GMT
Q1 2018 AMAG Pharmaceuticals Inc Earnings Call
- Zacks•2 months ago
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.
- Associated Press•2 months ago
AMAG Pharmaceuticals: 1Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of $1.59 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance
Strong first quarter execution with two FDA approvals and submission of a new drug application. Conference call scheduled for 8:00 a.m. ET today. WALTHAM, Mass., May 03, 2018-- AMAG Pharmaceuticals, Inc. ...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. In his role at AMAG, Mr. Butcher is responsible for leading the company’s overall business development efforts, with a focus on continuing to expand the portfolio with products that address unmet patient needs. Additionally, he oversees the company's alliance management team, and leads the corporate strategy function in close collaboration with Mr. Heiden, the senior leadership team, and the board of directors.
- Simply Wall St.•3 months ago
Calculating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
I am going to run you through how I calculated the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., April 27, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. Deutsche Bank Annual Health Care Conference ...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ET
WALTHAM, Mass., April 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. ...
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial — Discovering Underlying Factors of Influence
NEW YORK, April 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AMAG presentation 8-Mar-17 3:25pm GMT
AMAG Pharmaceuticals Inc at Raymond James Institutional Investors Conference
- Zacks•4 months ago
AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•4 months ago
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.
